Multiple sclerosis (MS) is a neurodegenerative disorder that damages the nerves in the brain and spinal cord, leading to problems with muscle movement, balance, and vision. MS is an example of a ...

– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...

Ocrelizumab (Ocrevus) is a prescription medication that targets certain B cells in your body’s immune system. The Food and Drug Administration (FDA) has approved ocrelizumab to treat relapse-remitting ...

– Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with ...

Primary progressive multiple sclerosis (PPMS) symptoms usually worsen steadily over time, often without remission. It can be harder to diagnose than relapsing-remitting multiple sclerosis (RRMS). PPMS ...

Primary progressive multiple sclerosis (PPMS) is an uncommon form of MS that affects approximately 10-15% of MS patients. In PPMS, symptoms steadily get worse over time without frequent relapses or ...

MISSISSAUGA, ON, March 19, 2019 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of ...

I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.